EUVIMEDEUVIMED entdecken
Crossref

Common Genetic Variants Near SLC2A2 and Glycemic Response to Glimepiride in the GRADE Comparative Effectiveness Clinical Trial

Josephine H Li iD, Lukasz Szczerbinski iD, Mark Tripputi, Haiyin Liu, Stella Nam, Endrina Mujica, Anastasia Emmanouilidou, Thinley Y Wangden, Anna Citko-Rojewska, Paulina Konopka, Marcin Czajkowski, Alicia Huerta-Chagoya und 23 weitere

Diabetes Care · 05.11.2026

DOI: 10.2337/dc26-1633 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, online erschienen am 05.11.2026. Verfasst von Josephine H Li und 34 weiteren Autor:innen. Beteiligte Einrichtung: Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA. Gefördert von: Accelerating Medicinces Partnership for Common Metabolic Disorders, JG CDC HHS, Hjärt-Lungfonden.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Optimizing second-line therapy for type 2 diabetes remains challenging because of interindividual variability in response. Current treatment selection does not consider personal genetic profiles. To address this gap, we conducted a pharmacogenomic genome-wide association study (GWAS) in a randomized comparative effectiveness trial to identify genetic predictors of glycemic response to insulin glargine, glimepiride, liraglutide, and sitagliptin when added to metformin. RESEARCH DESIGN AND METHODS In the Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness Study (GRADE), we performed a GWAS for the time to reach primary (glycated hemoglobin [HbA1c] ≥7%) and secondary (HbA1c >7.5%) metabolic failure. We conducted replication in independent cohorts, performed fine mapping of the top variants near SLC2A2, evaluated them for physiologic impact using oral glucose tolerance testing (OGTT) and response to acute glipizide challenge, and characterized glycemic response to glimepiride in an slc2a2-mutated zebrafish model. RESULTS rs2129019 in SLC2A2 encoding GLUT2 was enriched in African/African American participants and conferred a 38% increased risk of metabolic failure per A allele on glimepiride (P = 1.55 × 10−8). Carriers had impaired β-cell function, evidenced by a lower C-peptide index during OGTT, and diminished glucose-lowering response to acute sulfonylurea challenge. Genetic manipulation in zebrafish confirmed that slc2a2 disruption attenuated the glucose-lowering effect of glimepiride. CONCLUSIONS Genetic variation influences glycemic response to glucose-lowering medications, with SLC2A2 emerging as a genetic factor that modulates sulfonylurea response. These findings warrant further study to evaluate whether low-response allele carriers would benefit from alternative glucose-lowering therapies to advance precision diabetes care.

Autor:innen und Institutionen

  • Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
  • Diabetes Unit, Department of Medicine, Massachusetts General Hospital, Mass General Brigham, Boston, MA.
  • Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA.
  • Department of Medicine, Harvard Medical School, Boston, MA.
  • Clinical Research Center, Medical University of Bialystok, Bialystok, Poland.
  • Biostatistics Center, Department of Biostatistics and Bioinformatics, Milken Institute School of Public Health, George Washington University, Rockville, MD.

ORCID-Profile: Josephine H Li, Lukasz Szczerbinski, Aaron Leong, James B Meigs, Maggie Y Ng, Marie Pigeyre, Hertzel C Gerstein, Deepak L Bhatt, Christian T Ruff, Adam Y Dawed, Ewan R Pearson, Leslie S Satin, Steven E Kahn, Naji Younes, Josep M Mercader, Jose C Florez

Förderung

  • Accelerating Medicinces Partnership for Common Metabolic Disorders
  • JG CDC HHS
  • Hjärt-Lungfonden
  • Ministerstwo Zdrowia
  • Vetenskapsrådet
  • NHLBI NIH HHS
  • American Diabetes Association
  • NIDDK NIH HHS

Zitieren

APA

Li, J. H., Szczerbinski, L., Tripputi, M., Liu, H., Nam, S., Mujica, E., Emmanouilidou, A., Wangden, T. Y., Citko-Rojewska, A., Konopka, P., Czajkowski, M., Huerta-Chagoya, A., Vora, M., Leong, A., Meigs, J. B., Ng, M. Y., Loos, R. J. F., Pigeyre, M., Gerstein, H. C., …, & GRADE Research Group (2026). Common Genetic Variants Near SLC2A2 and Glycemic Response to Glimepiride in the GRADE Comparative Effectiveness Clinical Trial. Diabetes Care. https://doi.org/10.2337/dc26-1633

Vancouver

Li JH, Szczerbinski L, Tripputi M, Liu H, Nam S, Mujica E, et al. Common Genetic Variants Near SLC2A2 and Glycemic Response to Glimepiride in the GRADE Comparative Effectiveness Clinical Trial. Diabetes Care. 2026. doi:10.2337/dc26-1633

BibTeX
@article{Li2026,
  author = {Li, Josephine H and Szczerbinski, Lukasz and Tripputi, Mark and Liu, Haiyin and Nam, Stella and Mujica, Endrina and Emmanouilidou, Anastasia and Wangden, Thinley Y and Citko-Rojewska, Anna and Konopka, Paulina and Czajkowski, Marcin and Huerta-Chagoya, Alicia and Vora, Maheak and Leong, Aaron and Meigs, James B and Ng, Maggie Y and Loos, Ruth J F and Pigeyre, Marie and Gerstein, Hertzel C and Moura, Filipe A and Lai, Yi-Pin and Bhatt, Deepak L and Marston, Nicholas A and Ruff, Christian T and Sabatine, Marc S and Dawed, Adam Y and Pearson, Ewan R and Satin, Leslie S and den Hoed, Marcel and Kretowski, Adam and Kahn, Steven E and Younes, Naji and Mercader, Josep M and Florez, Jose C and GRADE Research Group, GRADE Research Group},
  title = {Common Genetic Variants Near SLC2A2 and Glycemic Response to Glimepiride in the GRADE Comparative Effectiveness Clinical Trial},
  journal = {Diabetes Care},
  year = {2026},
  doi = {10.2337/dc26-1633}
}
Kostenlos starten →